Edesa Biotech
Edesa Biotech
EDSA
NASDAQ
2.53
USD
6.30%
About
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses.
It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition.
It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.6K |
| Three Month Average Volume | 193.8K |
| High Low | |
| Fifty-Two Week High | 8.3331 USD |
| Fifty-Two Week Low | 2.4603 USD |
| Fifty-Two Week High Date | 12 Oct 2023 |
| Fifty-Two Week Low Date | 11 Oct 2023 |
| Price and Volume | |
| Current Price | 4.5 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.49% |
| Thirteen Week Relative Price Change | -2.90% |
| Twenty-Six Week Relative Price Change | -14.91% |
| Fifty-Two Week Relative Price Change | -39.43% |
| Year-to-Date Relative Price Change | -16.85% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 3.93% |
| Twenty-Six Week Price Change | -6.44% |
| Five Day Price Change | 1.12% |
| Fifty-Two Week Price Change | -24.10% |
| Year-to-Date Price Change | -1.53% |
| Month-to-Date Price Change | -15.09% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.29194 USD |
| Book Value Per Share (Most Recent Quarter) | 0.88289 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.5831 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.23495 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.61104 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.92921 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.20906 USD |
| Normalized (Last Fiscal Year) | -2.92921 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.92921 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.20906 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.92921 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.20906 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.74328 USD |
| Cash Per Share (Most Recent Quarter) | 0.62847 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.86504 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.14836 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.7183 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -31.16% |
| Tangible Book Value (5 Year) | -15.48% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 23.55% |
| EPS Change (Trailing Twelve Months) | 38.06% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 19 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,040,880 |
| Net Debt (Last Fiscal Year) | -5,361,400 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,636,480 |
| Free Cash Flow (Trailing Twelve Months) | -5,391,190 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -81.84% |
| Return on Assets (Trailing Twelve Months) | -94.60% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -101.88% |
| Return on Equity (Trailing Twelve Months) | -129.29% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -101.49% |
| Return on Investment (Trailing Twelve Months) | -128.81% |
| Return on Investment (5 Year) | -99,999.99% |